口腔黏膜片劑市場規模、佔有率和成長分析：按藥物類別、治療應用、分銷管道、最終用戶、患者群體和地區分類－2026-2033年產業預測

2024 年全球口腔黏膜片劑市場價值為 3.426 億美元，預計到 2033 年將從 2025 年的 3.6795 億美元成長到 6.5137 億美元，預測期（2026-2033 年）的複合年成長率為 7.4%。

由於口腔黏膜吸收片劑具有獨特的優勢，全球口腔固態吸收片劑市場正經歷顯著成長。這種片劑可在口腔內溶解，從而繞過首過代謝，提高藥物遞送效率。對於吞嚥困難的患者而言，這種方法尤其有益，因為它能更快地起效並提高生物利用度。對快速起效、以患者為中心的治療方案（例如用於治療噁心和慢性疼痛）的需求不斷成長，推動了這一市場的成長，而口腔黏膜Fentanyl正逐漸成為注射用鴉片類藥物的首選替代方案。遠端醫療進一步加速了口腔黏膜製劑在家中的使用。此外，人工智慧驅動的製劑最佳化正在透過改善藥物開發流程來改變市場，最終提高患者依從性，拓展治療選擇，並在全球各個領域創造新的商機。

全球口腔含片市場按藥物類別、治療應用、分銷管道、最終用戶、病患小組和地區進行細分。依藥物類別分類，市場分為鎮痛藥、鴉片類藥物成癮治療、荷爾蒙療法、止吐藥和其他藥物。依治療應用分類，市場分為疼痛管理、戒菸、荷爾蒙補充療法、神經系統疾病和其他疾病。按分銷管道分類，市場分為醫院藥房、零售藥房、線上藥房和其他管道。按最終用戶分類，市場分為醫院、專科診所、居家醫療和其他機構。依患者群體分類，市場分為兒童、成人、老年人和其他人群。依地區分類，市場分為北美、歐洲、亞太、拉丁美洲以及中東和非洲。

全球口腔黏膜吸收錠劑市場的成長要素

全球口腔片劑市場成長的驅動力在於，人們對無需吞嚥即可透過口腔黏膜快速吸收的非侵入性給藥方式的需求日益成長。患者越來越傾向於選擇口腔片劑，因為它們服用方便，感覺隱蔽，從而提高了遵守用藥，並最大限度地減少了傳統口服片劑的副作用。這一趨勢促使製藥公司加強研發投入，將創新口腔製劑納入產品平臺。此外，口腔片劑的便利性尤其受到老年人和兒童的青睞，進一步擴大了潛在用戶群體，並推動了市場成長。

全球口腔黏膜片劑市場的限制因素

全球口腔片劑市場面臨許多挑戰，這些挑戰可能會阻礙其成長。全面的安全性和有效性評估需要大量的臨床數據來證明其生物利用度穩定且副作用最小，這會使研發過程變得複雜。監管機構通常要求進行一系列全面的體外和體內研究，導致研發週期延長和成本增加。此外，為滿足不同地區的法規要求而需進行的複雜申請程序也阻礙了中小企業進入市場，從而延緩了新產品的上市。這種情況可能會促使投資者尋求監管程序更簡便的其他劑型。

全球口腔黏膜片劑市場趨勢

全球口腔片劑市場正經歷著向以患者為中心的給藥創新模式的顯著轉變，這主要得益於患者對易於給藥、起效迅速且能最大限度減少吞嚥不適的劑型需求不斷成長。製藥公司正日益採用口腔片劑作為首選解決方案，透過利用口味掩蔽技術、可自訂的劑量選擇和隱蔽包裝來提升用戶滿意度。這種對便利性和依從性的關注正在重塑產品開發平臺，促進與數位公司的合作，並最終加速過敏、荷爾蒙補充療法和慢性疼痛管理等領域製劑的上市。因此，口腔片劑市場在多個治療領域都變得更具吸引力。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球口腔黏膜片劑市場規模：依藥物類別分類

• 止痛藥
• 鴉片類藥物成癮治療藥物
• 荷爾蒙療法
• 止吐藥
• 其他

全球口腔黏膜片劑市場規模：依治療應用分類

• 疼痛管理
• 禁止抽煙
• 荷爾蒙補充療法
• 神經病變
• 其他

全球口腔黏膜片劑市場規模：依通路分類

• 醫院藥房
• 零售藥房
• 網路藥房
• 其他

全球口腔黏膜片劑市場規模：依最終用戶分類

• 醫院
• 專科診所
• 居家照護
• 其他

全球口腔黏膜片劑市場規模：依病患小組分類

• 兒童
• 成人
• 老年人
• 其他

全球口腔黏膜片劑市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Dr. Reddy's Laboratories Ltd.
• Cipla Limited
• Zydus Lifesciences Limited
• Lupin Limited
• Aurobindo Pharma Limited
• Orexo AB
• Aquestive Therapeutics, Inc.
• Viatris Inc.
• Indivior PLC
• Boehringer Ingelheim International GmbH
• GlaxoSmithKline plc
• Sanofi SA
• Bayer AG
• AstraZeneca plc
• Johnson & Johnson
• AbbVie Inc.
• F. Hoffmann-La Roche Ltd.

結論與建議

Global Buccal Tablets Market size was valued at USD 342.6 Million in 2024 and is poised to grow from USD 367.95 Million in 2025 to USD 651.37 Million by 2033, growing at a CAGR of 7.4% during the forecast period (2026-2033).

The global buccal tablet market is witnessing significant growth due to the unique advantages of solid dosage forms that dissolve in the inner cheek, thus bypassing first-pass metabolism and enhancing drug delivery efficiency. This method is particularly beneficial for patients with dysphagia, offering rapid onset of action and improved bioavailability. The increasing demand for fast-acting, patient-centered treatments for conditions like nausea and chronic pain is fueling this growth, with buccal fentanyl emerging as a preferred alternative to injectable opioids. Telemedicine is further facilitating the use of buccal formulations at home. Additionally, AI-driven formulation optimization is transforming the market by enhancing drug development processes, which ultimately improves patient adherence and expands therapeutic possibilities, creating new revenue opportunities across diverse demographics globally.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Buccal Tablets market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Buccal Tablets Market Segments Analysis

The global buccal tablets market is segmented by drug class, therapeutic application, distribution channel, end user, patient group and region. Based on drug class, the market is segmented into Analgesics, Opioid Dependence Treatments, Hormonal Therapies, Antiemetics and Others. Based on therapeutic application, the market is segmented into Pain Management, Smoking Cessation, Hormone Replacement Therapy, Neurological Disorders and Others. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others. Based on end user, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on patient group, the market is segmented into Pediatric, Adult, Geriatric and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Buccal Tablets Market

The Global Buccal Tablets market is propelled by the growing demand for non-invasive dosage forms that offer rapid absorption through the oral mucosa without the need for swallowing. Patients increasingly prefer buccal tablets for their ease of administration and discreet usage, which enhances compliance and minimizes side effects associated with traditional oral tablets. This trend motivates pharmaceutical companies to invest in research and development, leading to a focus on innovative buccal formulations in their product pipelines. Additionally, the convenience of buccal tablets makes them particularly appealing to elderly and pediatric populations, further broadening the potential user base and fostering market growth.

Restraints in the Global Buccal Tablets Market

The Global Buccal Tablets market faces significant challenges that may hinder its growth. The need for thorough safety and efficacy assessments requires extensive clinical data to demonstrate consistent bioavailability and minimal discomfort, which can complicate the development process. Regulatory agencies often mandate a comprehensive series of in-vitro and in-vivo studies, leading to increased development timelines and costs. Furthermore, the intricate filing processes needed to meet varying regional regulations deter smaller companies from entering the market, consequently slowing down the introduction of new products. This situation may drive investors towards alternative dosage forms with more straightforward regulatory pathways.

Market Trends of the Global Buccal Tablets Market

The Global Buccal Tablets market is experiencing a significant shift towards patient-centric delivery innovations, driven by a growing demand for easy-to-administer dosage forms that offer fast onset with minimal swallowing discomfort. Pharmaceutical companies are increasingly adopting buccal tablets as a favored solution, leveraging taste-masking technologies, customizable dosage options, and discreet packaging to enhance user satisfaction. This focus on convenience and adherence is reshaping product development pipelines and fostering collaborations with digital firms, ultimately expediting the introduction of formulations targeting allergies, hormone replacement therapy, and chronic pain management. Consequently, the market is becoming more appealing across various therapeutic categories.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Buccal Tablets Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Analgesics
• Opioid Dependence Treatments
• Hormonal Therapies
• Antiemetics
• Others

Global Buccal Tablets Market Size by Therapeutic Application & CAGR (2026-2033)

• Market Overview
• Pain Management
• Smoking Cessation
• Hormone Replacement Therapy
• Neurological Disorders
• Others

Global Buccal Tablets Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Global Buccal Tablets Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Homecare
• Others

Global Buccal Tablets Market Size by Patient Group & CAGR (2026-2033)

• Market Overview
• Pediatric
• Adult
• Geriatric
• Others

Global Buccal Tablets Market Size & CAGR (2026-2033)

• North America (Drug Class, Therapeutic Application, Distribution Channel, End User, Patient Group)
  • US
  • Canada
• Europe (Drug Class, Therapeutic Application, Distribution Channel, End User, Patient Group)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Therapeutic Application, Distribution Channel, End User, Patient Group)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Therapeutic Application, Distribution Channel, End User, Patient Group)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Therapeutic Application, Distribution Channel, End User, Patient Group)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Lifesciences Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Orexo AB
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aquestive Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Indivior PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations